恶性肿瘤“免疫——化学”疗法初试  

IMMUNO-CHEMOTHERAPY OF CERTAIN MALIGNANT NEOPLASMS

作　　者：程广泽[1] 吴功侃[1] 夏坤 

机构地区：[1]大连医学院肿瘤学教研室

出　　处：《大连医学院学报》1992年第1期6-9,共4页

摘　　要：70年代初期,作者将只用于皮肤试验的二硝基氯苯(DNCB),引伸治疗各种皮肤、疣赘及皮肤恶性肿瘤,均获得良好效果。在国内首先提出疣与体表肿瘤的免疫排斥疗法。鉴于肿瘤患者的免疫能力往往偏低,单靠其自身免疫力不足于控制住顽强增殖的癌细胞,而化疗药物对癌细胞的杀灭呈几何级数,欲全部消灭体内癌细胞单靠化疗也有困难,本文将免疫与化疗结合,以易于客观观察的皮肤恶性肿瘤为模板,试验治疗了20例经病理学确诊的癌瘤,取得18例有效(90%)、15例痊愈(75%)的临床效果。并对15例痊愈者进行了长期随访。方法简便、安全、有效,值得进一步深入探讨。From 1977 to 1985, 20 cases of various malignant skin lesions (squemous cell carcinoma of skin 11, basal cell 2, cancer of lip 3, facial malignant melanoma, cancer of tongue, vulva and Bowen's disease each one. All 20 cases were confirmed by pathology) were successfully treated with immuno-chemotherapy, mainly with DNCB, BCG, PHA, 5Fu, Thio-TEPA and a number of traditional Chinese medicinal herbs collectingly known as Fu-Zheng (扶正) therapy. None of these patients were treated with surgery or irradiation. Among the 20 cases, the cure rate is 75% (15/20) and the response rate is 90% (18/20). The 15 cases of complete regression were followed-up for more than 10 years. Chemotherapy, though it is essential to cancer management, is believed to further lower the already low cellular immunologic response of cancer patients giving poorer prognosis. We consider that the combination of immuno-chemotherapy do improve the immunecompetence, the natural host defence function in cancer patients.

关 键 词：恶性 肿瘤 免疫化学疗法 

分 类 号：R730.51[医药卫生—肿瘤]